FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:08:113 | Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors - insights from the AMBI-RA study Riccardo Bertola1, Beatrice Maranini1, Carlo Garaffoni1, Maria Pozzuto1, Anna Laura Riva Cambrino1, Alessandro Spinelli1, Letizia Mamprin1, Federico Agostini1, Martina Di Nunzio1, Marcello Govoni1, Alessandra Bortoluzzi1, Ettore Silvagni1 | 1Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Italy
151 -
PO:03:036 | Psoriatic arthritis: does pre-existing treatment with cs/bDMARDs for psoriasis influence the characteristics and outcomes of joint disease? Ilenia Marchesini1, Alberto Floris1, Cristina Mugheddu2, Laura Li Volsi1, Maria Teresa Paladino1, Roberta Origa1, Jessica Sorgia1, Mattia Congia1, Elisabetta Chessa1, Matteo Piga1, Caterina Ferreli2, Laura Atzori2, Alberto Cauli1 | 1Unità di Reumatologia, AOU e Università di Cagliari-Monserrato; 2Unità di Dermatologia, AOU e Università di Cagliari, Italy
160 -
PO:06:086 | Updated Systematic Literature Review and meta-analysis to Inform the Italian Society of Rheumatology Recommendations on the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease Angelo Fassio1, Marco Sebastiani9|10, Francesco Pollastri1, Chiara Crotti4, Nicola Ughi5, Enrico De Lorenzis6, Silvia Mancuso7, Massimo Radin8, Francesca Cozzini9, Greta Carrara11, Gianpiero Landolfi11, Roberto Rozza11, Andreina Manfredi2|3 | 1Rheumatology Unit, University of Verona, Verona, Italy; 2University of Modena and Reggio Emilia, Reggio Emilia, Italy; 3Rheumatology Unit, AUSL-IRCCS, Reggio Emilia, Italy; 4Bone Disease Unit, Department of Rheumatology and Medical Science, ASST-G.Pini-CTO, Milan, Italy; 5Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 6Department of Aging Diseases, Orthopedic and Rheumatology, Rheumatology Division, P. Gemelli, Roma, Italy; 7Rheumatology Unit, Department of Clinical, Internal, Anaesthesiologic and Cardiovascular, Sciences, Sapienza, Roma, Italy; 8CMID, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy; 9Department of Medicine and Surgery, University of Parma, Parma, Italy; 10Rheumatology Unit, AUSL Piacenza, Piacenza, Italy; 11Unità Epidemiologica, SIR, Società Italiana di Reumatologia, Milano, Italy
15 -
PO:07:095 | Clinical impact of therapeutic modification following changes in AIFA reimbursement criteria for JAK inhibitors in patients with RA in remission/low disease activity: analysis of the multicenter JAK-SWAP RER study in Emilia-Romagna Marta Raschella1, Giulia Furia1, Martina Di Nunzio1, Francesco Luca Renzullo2, Francesco Girelli2, Federica Pignatti3, Francesco Ursini3, Licia Vultaggio4, Pierluigi Cataleta4, Elena Bravi5, Eugenio Arrigoni5, Francesca Bergossi6, Enrica Vandelli7, Massimo Reta6|7, Viola Magnani8, Andreina Manfredi8|9, Giuseppe Germanò8, Alessandra Bortoluzzi1, Marcello Govoni1, Ettore Silvagni1 | 1Unità Operativa Complessa di Reumatologia, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara e Azienda Ferrara; 2UOS Reumatologia, Ospedale GB Morgagni, Forlì; 3UOC Reumatologia, Istituto ortopedico Rizzoli, Bologna; 4UO Reumatologia, AUSL Romagna Ospedale di Ravenna; 5UO Reumatologia, Azienda USL di Piacenza; 6Reumatologia Osp. Maggiore, Bologna; 7UO Medicina Interna ad Indirizzo Reumatologico Interaziendale SC AUSL Bologna, IRCCS Policlinico di SantOrsola, Bologna; 8U.O Reumatologia, Santa Maria Nuova di Reggio Emilia; 9Università degli studi di Modena e Reggio Emilia, Italy
149 -
PO:08:124 | An exploratory analysis of risk factors for methotrexate-associated osteopathy: a retrospective study Federico Aldegheri1, Francesca Ruzzon1, Matteo Appoloni1, Maurizio Rossini1, Giovanni Adami1, Davide Gatti1, Ombretta Viapiana1, Angelo Fassio1 | 1Università di Verona, Italy
22 -
PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet's disease treated with infliximab - a real-life study Antonello Sulis1, Federica Di Cianni1, Maria Laura Manca2, Rosaria Talarico1, Marta Mosca1. | 1Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; 2Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy.
145 -
PO:01:010 | Survival of second-line treatment with TNF inhibitors vs. IL-23 inhibitors after failure of a first TNF inhibitor: a real-life observational study from the Italian multicenter BIRRA cohort in patients with psoriatic arthritis Francesca Ometto1, Olga Addimanda2, Bernd Raffeiner3, Alberto Lo Gullo4, Elisa Visalli5, Eleonora Celletti6, Antonella Farina7, Maddalena Larosa8, Romina Andracco9, Marino Paroli10, Patrizia Del Medico11, Aldo Biagio Molica Collella12, Federica Lumetti13, Gilda Sandri14, Marta Priora15, Aurora Ianiello16, Elena Bravi17, Alessandra Bezzi18, Palma Scolieri19, Simone Parisi20, Viviana Ravagnani20, Rosetta Vitetta20, Luca Idolazzi20, Riccardo Bixio20, Gianluca Santoboni20, Francesco Girelli20, Alarico Ariani20 | 1Azienda ULSS 6 Euganea, Padova; 2UOC Interaziendale di Medicina Interna ad Indirizzo Reumatologico, AUSL BO - IRCCS AOU Bologna; 3Unità di Reumatologia, Teaching Hospital of the Paracelsius Medical University, Central Hospital of Bolzano (ASAA-SABES) Bolzano; 4UOD Reumatologia, ARNAS Garibaldi Catania; 5UO Reumatologia, Policlinico San Marco Hospital Catania; 6UOS Reumatologia, Ospedale SS. Annunziata, Università G. d'Annunzio, Chieti; 7UOC Medicina Interna- Ambulatorio Reumatologico, Ospedale A. Murri, Fermo; 8S.C. Reumatologia, Dipartimento Specialità Mediche, Ospedale La Colletta-Azienda Sanitaria Locale 3 Genova; 9Ambulatorio Reumatologia, Ospedale di Imperia; 10Sapienza Università Polo Pontino, Latina; 11Ambulatorio di Reumatologia, UO Medicina Interna, Civitanova Marche Hospital, Civitanova (MC); 12UOSD di Reumatologia, Azienda Ospedaliera Papardo Messina; 13Unità di Reumatologia, Azienda USL di Modena e Ospedale Universitario Policlinico di Modena; 14Unità di Reumatologia, Università di Modena e Reggio Emilia Modena; 15Ambulatorio e Day Hospital di Reumatologia, ASL CN1, Mondovì (CN); 16Poliambulatorio specialistico di reumatologia e Day Hospital multidisciplinare di area Medica, ASL Novara; 17UOSD Reumatologia, Ospedale G. Da Saliceto, Piacenza; 18UO Medicina Interna e Reumatologia, SS Reumatologia, ASL Romagna, Rimini; 19UOC Medicina Interna e Reumatologia, Ospedale Nuovo Regina Margherita, Roma; 20Gruppo BIRRA Italy
167 -
-
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
143 -
PO:07:098 | Reasons for treatment failure and their synovial correlate among patients with difficult-to-treat rheumatoid arthritis Alessandro Giollo1, Mariangela Salvato1, Francesca Frizzera1, Kiren Khalid1, Lorenzo Di Luozzo1, Carlo Garaffoni2, Maria Capita2, Marianna Tamussin2, Giovanni Lanza2, Marny Fedrigo3, Annalisa Angelini3, Roberta Ramonda1, Ettore Silvagni2, Andrea Doria1 | 1UOC Reumatologia Padova, Italy; 2UOC Reumatologia Ferrara, Italy; 3UOC Patologia cardiovascolare Padova, Italy; 4UOC Anatomia Patologica Ferrara, Italy
16 -
PO:03:044 | Impact of Inflammatory Bowel Disease on Clinical Phenotype and Treatment Response in Patients with Psoriatic Arthritis Maria Morrone1, Maria Giannotta1, Vincenzo Venerito1, Greta Giulia Dipietrangelo1, Stefano Stano1, Florenzo Iannone1, Giuseppe Lopalco1 | 1Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy
27 -
PO:08:119 | Infusional Advantage: Rituximab’s Role in Enhancing Adherence in Multimorbid Rheumatoid Arthritis Marco Capodiferro1, Daniele Domanico1, Angelica Napoletano1, Giulia Righetti2, Patrizia Suppressa2, Vincenzo Venerito1, Giuseppe Lopalco1, Florenzo Iannone1, Fabio Cacciapaglia1|2 | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Jonian Area DiMePRe-J University of Bari, Italy; 2Department of Medicine and Surgery, Miulli General Hospital Acquaviva delle Fonti - LUM University Casamassima Bari Acquaviva delle Fonti, Bari, Italy
12 -
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
2152PDF: 390SUPPLEMENTARY MATERIAL: 339 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
145 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
146 -
PO:20:007 | Mind the rebound: ctx dynamics after denosumab discontinuation and zoledronate rescue in patients with postmenopausal osteoporosis or with cancer treatment-induced bone loss Federico Aldegheri1, Francesca Ruzzon1, Matteo Appoloni1, Giovanni Adami1, Davide Gatti1, Maurizio Rossini1, Angelo Fassio1, Ombretta Viapiana1 | 1Università di Verona, Italy
31 -
PO:11:162 | DRESS syndrome: a case treated with mepolizumab Alessandro Belotti Masserini1, Stefania Bertocchi1, Eleonora Bruschi1, Silvia Breda1, Valeria Rossi1, Elide Lupi1, Tania Ubiali1, Fabrizio Angeli1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII, Bergamo, Italy
150 -
PO:29:131 | Early effect of auricular acupuncture on pain modulation in patients with fibromyalgia: findings from a real-life experience Benedetta Bianchi1, Edoardo Cipolletta1, Sonia Farah1, Fausto Salaffi1, Marco Di Carlo1 | 1Clinica Reumatologica, Università Politecnica delle Marche, ospedale Carlo Urbani Jesi, Ancona, Italy
27 -
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Hn Harris4, Ciara O'Shea5, Roger A. Levy6, Andrea Doria7 | 1Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; 2Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; 3Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; 4GSK, Immunologia Biostatistica London, UK; 5GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; 6GSK, Global Medical Affairs Collegeville, PA, USA; 7Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy
149 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
269
